Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Wound complications · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) probably leads to higher adverse wound outcomes: all complications compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 2.56 [1.94, 3.36]
12 studies · 1679 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: primary outcomes

Wound complications · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) probably leads to higher adverse wound outcomes: all complications compared with antimetabolites: primary outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 1.56 [1.28, 1.9]
17 studies · 6913 participants
Moderate

Intervention not reported

Adverse wound outcomes: all complications · primary immunosuppression in kidney transplant recipients

The intervention showed no clear difference in adverse wound outcomes: all complications (low certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 0.95 [0.53, 1.71]
3 studies · 291 participants
Low